AbbVie: The Only Big Pharma Stock I'd Consider a Buy‑and‑Never‑Sell

The company's ability to hold off generic competitors long enough to develop a pair of replacement drugs for Humira that are ...
Medical News Today

Humira interactions: Alcohol, medications, and other factors

As with other medications, Humira can interact with certain other drugs. It can also interact with some vaccines. An interaction occurs when one substance causes another substance to have a different ...
Northcountrypublicradio.org

Copycat drugs could end Humira's reign as the prominent arthritis treatment

The arthritis drug Humira has been a blockbuster seller for more than two decades. Now some copycats could end Humira's reign. Copycat drugs could end Humira's reign as the prominent arthritis ...
STAT

More Medicare plans cover Humira biosimilars, but do little to encourage patient use

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
WWLP-22News

Health New England to replace Humira coverage with lower-cost biosimilars

SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of ...
Monthly Prescribing Reference

FDA Designates Yuflyma an Interchangeable Biosimilar to Humira

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...
Nasdaq

AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock

AbbVie ABBV stock has risen 8.0% in six months, adding more than $24 billion to its market value. AbbVie has successfully navigated the loss of exclusivity (“LOE”) of its blockbuster drug, Humira, by ...